IO Biotech Stock Forum

$IO Biotech (IOBT.US)$ Reuters· 08:051min
IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer

$IO Biotech (IOBT.US)$
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
Thursday, 9th January at 8:05 am
-- Enrollment Completed Ahead of Schedule --
-- Initial Data Expected in 2025 --
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, ...

$IO Biotech (IOBT.US)$ Reuters· 3 mins ago
IO Biotech Secures up to €57.5 Million in Debt Financing From the European Investment Bank

$IO Biotech (IOBT.US)$
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...